Kopran shines as its arm receives approval from USFDA for supply of API Atenolol

18 Jun 2020 Evaluate

Kopran is currently trading at Rs. 39.65, up by 2.50 points or 6.73% from its previous closing of Rs. 37.15 on the BSE.

The scrip opened at Rs. 37.10 and has touched a high and low of Rs. 40.85 and Rs. 36.80 respectively. So far 148327 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 40.85 on 18-Jun-2020 and a 52 week low of Rs. 16.15 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 40.85 and Rs. 29.15 respectively. The current market cap of the company is Rs. 175.39 crore.

The promoters holding in the company stood at 43.78%, while Institutions and Non-Institutions held 2.41% and 53.81% respectively.

Kopran’s wholly owned subsidiary company -- Kopran Research Laboratories has received approval from Unites States Food and Drug Administration (USFDA) for supply of API Atenolol to the US market. The company had filed the DMF of Atenolol, which has now been approved by the USFDA

Earlier the subsidiary’s active Pharmaceutical Ingredients Manufacturing facility at Mahad was inspected by the USFDA in January 2019 without any observation under Para 483.

Kopran is working towards creating and maintaining a global presence. Presence in Africa through Kampala Pharmaceutical Industries (KPI), a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.

 

 

 

 

Kopran Share Price

135.60 -4.10 (-2.93%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×